173 related articles for article (PubMed ID: 30147330)
41. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.
Jin J; Si J; Liu Y; Wang H; Ni R; Wang J
Respir Res; 2018 Oct; 19(1):197. PubMed ID: 30290817
[TBL] [Abstract][Full Text] [Related]
42. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
43. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
44. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
45. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
46. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Jodai T; Saruwatari K; Ikeda T; Moriyama E; Kashiwabara K; Shingu N; Iyonaga K; Inaba M; Ajishi Y; Honda C; Hirosako S; Maruyama H; Kakiuchi Y; Eida H; Tomita Y; Saeki S; Ichiyasu H; Sakagami T
Int J Clin Oncol; 2021 Jan; 26(1):78-86. PubMed ID: 32965577
[TBL] [Abstract][Full Text] [Related]
48. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
49. Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.
Takada K; Shimokawa M; Akamine T; Ono Y; Haro A; Osoegawa A; Tagawa T; Mori M
Anticancer Res; 2019 Apr; 39(4):1987-1996. PubMed ID: 30952742
[TBL] [Abstract][Full Text] [Related]
50. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics.
Zhang J; Gao J; Li Y; Nie J; Dai L; Hu W; Chen X; Han J; Ma X; Tian G; Wu D; Shen L; Fang J
Thorac Cancer; 2015 Jul; 6(4):534-8. PubMed ID: 26273411
[TBL] [Abstract][Full Text] [Related]
51. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
To KKW; Fong W; Cho WCS
Front Oncol; 2021; 11():635007. PubMed ID: 34113560
[TBL] [Abstract][Full Text] [Related]
53. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
55. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
56. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
[TBL] [Abstract][Full Text] [Related]
57. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
Lantuejoul S; Damotte D; Hofman V; Adam J
J Thorac Dis; 2019 Jan; 11(Suppl 1):S89-S101. PubMed ID: 30775032
[TBL] [Abstract][Full Text] [Related]
58. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
[TBL] [Abstract][Full Text] [Related]
59. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Medjebar S; Truntzer C; Perrichet A; Limagne E; Fumet JD; Richard C; Elkrief A; Routy B; Rébé C; Ghiringhelli F
Oncoimmunology; 2020 Oct; 9(1):1836766. PubMed ID: 33178495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
